Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

Roy et al., medRxiv, doi:10.1101/2021.03.08.21252883
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Time to clinical response.. 2% primary Improvement Relative Risk HCQ for COVID-19  Roy et al.  EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 29 patients in India No significant difference in recovery c19hcq.org Roy et al., medRxiv, March 2021 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D, and zinc, comparing ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), and SOC (n=15), finding that all groups recover quickly, and there was no significant difference between the groups.
This study is excluded in the after exclusion results of meta analysis: no serious outcomes reported and fast recovery in treatment and control groups, there is little room for a treatment to improve results.
Study covers HCQ and ivermectin.
relative time to clinical response of wellbeing, 2.4% lower, relative time 0.98, p = 0.96, treatment 14, control 15, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Roy et al., 12 Mar 2021, retrospective, database analysis, India, preprint, 5 authors, dosage not specified.
This PaperHCQAll
Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study
Dr Sayak Roy, Shambo Samrat Samajdar, Santanu K Tripathi, Shatavisa Mukherjee, Kingshuk Bhattacharjee
doi:10.1101/2021.03.08.21252883
Introduction: With over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day clinicians are bombarded with many new treatment options that claim to be better than the others.
References
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Ciccullo, Borghetti, Dal Verme, Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line, Int J Antimicrob Agents
Healthworld, COVID-19: Health Ministry issues revised home isolation guidelines
Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series, Gut
Liu, Cao, Xu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Ncid, None
Oldenburg, Doan, Azithromycin for severe COVID-19, Lancet
Roy, Journey So Far With COVID 19 -A Comprehensive Review, European Journal Of Clinical And Experimental Medicine
Roy, Mainakmukhopadhyay, Ventricular arrhythmia risk based on ethnicity in COVID-19 patients on hydroxychloroquine and azithromycin combination: Viewpoint, SN Compr Clin Med
Ruan, Yang, Wang, Jiang, Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Med
Summary, Therapeutic management of patients with COVID-19
Velavan, Meyer, Mild versus severe COVID-19: Laboratory markers, Int J Infect Dis
Who, None
Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B
Zamanian, Pollack, Jr, Gentile, Outpatient inhaled nitric oxide in a patient with vasoreactive idiopathic pulmonary arterial hypertension and COVID-19 infection, Am J Respir Crit Care Med
{ 'institution': [{'name': 'medRxiv'}], 'indexed': { 'date-parts': [[2022, 12, 22]], 'date-time': '2022-12-22T05:31:07Z', 'timestamp': 1671687067555}, 'posted': {'date-parts': [[2021, 3, 12]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 20, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2021, 3, 22]]}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec><jats:title>Introduction</jats:title><jats:p>With ' 'over 87,273,380 cases being reported and 1,899,440 deaths worldwide as of 9th January 2021, ' 'Coronavirus disease 2019 (COVID-19) has become the worst-hit pandemic till date. Every day ' 'clinicians are bombarded with many new treatment options that claim to be better than the ' 'others.</jats:p></jats:sec><jats:sec><jats:title>Materials and ' 'methods</jats:title><jats:p>After screening the electronic database of COVID-19 patients ' 'retrospectively, 56 patients with mild COVID-19 infection matched the inclusion criteria and ' 'were divided into the four following groups - group having used Hydroxychloroquine (HCQ), ' 'group using doxycycline (DOX) + Ivermectin (IVR) combination, group receiving only ' 'azithromycin (AZ) and, group receiving only symptomatic treatment. The study’s primary ' 'objective was to see Clinical response of well-being (CRWB) reporting time after initiating ' 'treatment onset between the four different treatment ' 'arms.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>CRWB did not ' 'differ between the four groups receiving four different managements (p-value 0.846). There ' 'was significant correlation between blood levels of LDH (p-value 0.001), CRP (p-value 0.03) ' 'and D-dimer (p-value 0.04) with CRWB in IVR+DOX group and, between LDH (p-value 0.001), CRP ' '(p-value 0.01) and age (p-value 0.035) with CRWB in the symptomatic management ' 'group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Mild COVID-19 ' 'infection in patients having low-risk to progress can be managed symptomatically without any ' 'specific drug intervention.</jats:p></jats:sec>', 'DOI': '10.1101/2021.03.08.21252883', 'type': 'posted-content', 'created': {'date-parts': [[2021, 3, 12]], 'date-time': '2021-03-12T14:40:23Z', 'timestamp': 1615560023000}, 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic ' 'of West Bengal: A Retrospective study', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6185-9375', 'authenticated-orcid': False, 'given': 'Sayak', 'family': 'Roy', 'sequence': 'first', 'affiliation': []}, {'given': 'Shambo Samrat', 'family': 'Samajdar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Santanu K', 'family': 'Tripathi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-9524-1525', 'authenticated-orcid': False, 'given': 'Shatavisa', 'family': 'Mukherjee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kingshuk', 'family': 'Bhattacharjee', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2021032410001188000_2021.03.08.21252883v2.1', 'unstructured': 'Who.int. Accessed January 16, 2021. https://covid19.who.int/.'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.2', 'unstructured': 'Executive Summary. Therapeutic management of patients with COVID-19. ' 'Nih.gov. Accessed January 16, 2021. ' 'https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_100.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.3', 'unstructured': 'Gov.in. Accessed January 16, 2021. ' 'https://www.wbhealth.gov.in/uploaded_files/corona/WB_Covid_protocol_book_25.09_.20_(1)_.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.4', 'unstructured': 'HealthWorld ET. COVID-19: Health Ministry issues revised home isolation ' 'guidelines. PTI. Published July 3, 2020. Accessed January 16, 2021. ' 'https://health.economictimes.indiatimes.com/news/policy/covid-19-health-ministry-issues-revised-home-isolation-guidelines/76767874'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.5', 'unstructured': 'Clinical management of COVID-19. Who.int. Accessed January 16, 2021. ' 'https://www.who.int/publications/i/item/clinical-management-of-covid-19'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.6', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/gutjnl-2020-321852'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.7', 'first-page': '214', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'volume': '103', 'year': '2020', 'journal-title': 'Int J Infect Dis'}, { 'issue': '1', 'key': '2021032410001188000_2021.03.08.21252883v2.8', 'doi-asserted-by': 'crossref', 'first-page': '130', 'DOI': '10.1164/rccm.202004-0937LE', 'article-title': 'Outpatient inhaled nitric oxide in a patient with vasoreactive ' 'idiopathic pulmonary arterial hypertension and COVID-19 infection', 'volume': '202', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'issue': '5', 'key': '2021032410001188000_2021.03.08.21252883v2.9', 'doi-asserted-by': 'crossref', 'first-page': '766', 'DOI': '10.1016/j.apsb.2020.02.008', 'article-title': 'Analysis of therapeutic targets for SARS-CoV-2 and discovery of ' 'potential drugs by computational methods', 'volume': '10', 'year': '2020', 'journal-title': 'Acta Pharm Sin B'}, { 'issue': '8', 'key': '2021032410001188000_2021.03.08.21252883v2.10', 'first-page': '1', 'article-title': 'MainakMukhopadhyay. Ventricular arrhythmia risk based on ethnicity in ' 'COVID-19 patients on hydroxychloroquine and azithromycin combination: ' 'Viewpoint', 'volume': '2', 'year': '2020', 'journal-title': 'SN Compr Clin Med'}, { 'issue': '10256', 'key': '2021032410001188000_2021.03.08.21252883v2.11', 'doi-asserted-by': 'crossref', 'first-page': '936', 'DOI': '10.1016/S0140-6736(20)31863-8', 'article-title': 'Azithromycin for severe COVID-19', 'volume': '396', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.12', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41421-020-0156-0'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.13', 'unstructured': 'Ncid.sg. Accessed January 16, 2021. ' 'https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Documents/Treatment%20Guidelines%20for%20COVID-19%20%282%20Apr%202020%29%20-final.pdf'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.14', 'unstructured': 'Therapeutic Management. Nih.gov. Accessed January 16, 2021. ' 'https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.15', 'doi-asserted-by': 'crossref', 'unstructured': 'Roy, S. , 2020. Journey So Far With COVID 19 – A Comprehensive Review | ' 'European Journal Of Clinical And Experimental Medicine. [online] ' 'Ejcem.ur.edu.pl. Available at: ' '<http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review> ' '[accessed 17 January 2021]. ' 'http://www.ejcem.ur.edu.pl/summary/journey-so-far-covid-19-comprehensive-review', 'DOI': '10.15584/ejcem.2020.4.7'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.16', 'unstructured': 'Prophylactic Ivermectin in COVID-19 Contacts. Clinicaltrials.gov. ' 'Accessed January 16, 2021. ' 'https://clinicaltrials.gov/ct2/show/results/NCT04422561.'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.17', 'unstructured': 'USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of ' 'Covid 19 - Study Results - ClinicalTrials.Gov. Clinicaltrials.gov. ' 'Accessed January 16, 2021. ' 'https://clinicaltrials.gov/ct2/show/results/NCT04425850.'}, { 'issue': '2', 'key': '2021032410001188000_2021.03.08.21252883v2.18', 'doi-asserted-by': 'crossref', 'first-page': '106017', 'DOI': '10.1016/j.ijantimicag.2020.106017', 'article-title': 'Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a ' 'report from the Italian front line', 'volume': '56', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.04.061'}, { 'key': '2021032410001188000_2021.03.08.21252883v2.20', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00134-020-05991-x'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.03.08.21252883', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 21]], 'date-time': '2022-12-21T09:03:55Z', 'timestamp': 1671613435000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2021.03.08.21252883'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 3, 12]]}, 'references-count': 20, 'URL': 'http://dx.doi.org/10.1101/2021.03.08.21252883', 'relation': {}, 'published': {'date-parts': [[2021, 3, 12]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit